Palindromic Rheumatism Symptoms

Over 24 months, remission occurred in 55.9% of abatacept participants versus 22.9% of hydroxychloroquine participants. Attack intensity decreased to a median of 4.0 with abatacept but remained 7.0 with hydroxychloroquine. Abatacept produced clearer benefits for remission and attack intensity than hydroxychloroquine. Attacks lasting less than 24 hours were more common with abatacept than hydroxychloroquine over 24 months. Attack frequency decreased in both treatment groups, but median attack number did not differ significantly between groups.